JP2019511471A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511471A5 JP2019511471A5 JP2018543209A JP2018543209A JP2019511471A5 JP 2019511471 A5 JP2019511471 A5 JP 2019511471A5 JP 2018543209 A JP2018543209 A JP 2018543209A JP 2018543209 A JP2018543209 A JP 2018543209A JP 2019511471 A5 JP2019511471 A5 JP 2019511471A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide
- compound
- vrna
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 28
- 108020000999 Viral RNA Proteins 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 241000712431 Influenza A virus Species 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 7
- 206010022000 influenza Diseases 0.000 claims description 7
- 239000002777 nucleoside Substances 0.000 claims description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 4
- 210000002845 virion Anatomy 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 102000006382 Ribonucleases Human genes 0.000 claims description 2
- 108010083644 Ribonucleases Proteins 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims description 2
- 102200074039 rs1064583 Human genes 0.000 claims description 2
- 102200104662 rs121908730 Human genes 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 6
- 230000003442 weekly effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 239000012190 activator Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022162516A JP2022176378A (ja) | 2016-03-02 | 2022-10-07 | インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法 |
| JP2025061328A JP2025096365A (ja) | 2016-03-02 | 2025-04-02 | インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302548P | 2016-03-02 | 2016-03-02 | |
| US62/302,548 | 2016-03-02 | ||
| PCT/US2017/020241 WO2017151795A1 (en) | 2016-03-02 | 2017-03-01 | Pan-genotypic agents against influenza virus and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162516A Division JP2022176378A (ja) | 2016-03-02 | 2022-10-07 | インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511471A JP2019511471A (ja) | 2019-04-25 |
| JP2019511471A5 true JP2019511471A5 (https=) | 2020-03-19 |
| JP7536272B2 JP7536272B2 (ja) | 2024-08-20 |
Family
ID=59743201
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543209A Active JP7536272B2 (ja) | 2016-03-02 | 2017-03-01 | インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法 |
| JP2022162516A Withdrawn JP2022176378A (ja) | 2016-03-02 | 2022-10-07 | インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法 |
| JP2025061328A Pending JP2025096365A (ja) | 2016-03-02 | 2025-04-02 | インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162516A Withdrawn JP2022176378A (ja) | 2016-03-02 | 2022-10-07 | インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法 |
| JP2025061328A Pending JP2025096365A (ja) | 2016-03-02 | 2025-04-02 | インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10597658B2 (https=) |
| EP (3) | EP3800257B1 (https=) |
| JP (3) | JP7536272B2 (https=) |
| CN (1) | CN108778344A (https=) |
| CA (1) | CA3014776A1 (https=) |
| DK (1) | DK3800257T3 (https=) |
| ES (1) | ES2981765T3 (https=) |
| FI (1) | FI3800257T3 (https=) |
| HR (1) | HRP20240765T1 (https=) |
| HU (1) | HUE066977T2 (https=) |
| LT (1) | LT3800257T (https=) |
| PL (1) | PL3800257T3 (https=) |
| PT (1) | PT3800257T (https=) |
| RS (1) | RS65707B1 (https=) |
| SI (1) | SI3800257T1 (https=) |
| SM (1) | SMT202400253T1 (https=) |
| WO (1) | WO2017151795A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021201996A1 (en) * | 2020-02-14 | 2021-10-07 | The Board Of Trustees Of The Leland Stanford Junior University | Pan-genotypic agents against respiratory viruses and methods of using the same |
| US12522827B2 (en) | 2016-03-02 | 2026-01-13 | The Board Of Trustees Of The Leland Stanford Junior University | Pan-genotypic agents against influenza virus and methods of using the same |
| US11339392B2 (en) | 2016-03-02 | 2022-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Pan-genotypic agents against influenza virus and methods of using the same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT69956A (en) * | 1990-08-14 | 1995-09-28 | Isis Pharmaceuticals Inc | Methode for inhibition of influenza virus by antiseuse oligonucleotides |
| US20040242518A1 (en) | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
| US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| AU2006235364A1 (en) * | 2005-04-08 | 2006-10-19 | Marina Biotech, Inc. | RNAi therapeutic for respiratory virus infection |
| EP1937066A4 (en) * | 2005-08-18 | 2008-12-24 | Alnylam Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS DISEASES |
| WO2007084359A2 (en) * | 2006-01-17 | 2007-07-26 | Oligos Etc., Inc. | Compositions and methods for the treatment of influenza infection |
| CN100562342C (zh) * | 2006-01-17 | 2009-11-25 | 奥林格斯技术有限公司 | 防治流感病毒感染的寡核苷酸药物 |
| CA2666657A1 (en) * | 2006-10-18 | 2008-04-24 | Nastech Pharmaceutical Company Inc. | Nicked or gapped nucleic acid molecules and uses thereof |
| US20090042823A1 (en) | 2007-08-10 | 2009-02-12 | Mdrna, Inc. | Uses of broad spectrum rnai therapeutics against influenza |
| CA2729757A1 (en) * | 2008-07-01 | 2010-01-07 | The Johns Hopkins University | Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase |
| AU2009310557B2 (en) * | 2008-10-27 | 2014-09-11 | Academisch Ziekenhuis Leiden | Methods and means for efficient skipping of exon 45 in Duchenne Muscular Dystrophy pre-mRNA |
| EP2499248B1 (en) | 2009-11-13 | 2017-01-04 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| EP2519633B1 (en) * | 2009-12-29 | 2017-10-25 | CuRNA, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
| CA2800281C (en) * | 2010-06-01 | 2021-01-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
-
2017
- 2017-03-01 EP EP20208373.9A patent/EP3800257B1/en active Active
- 2017-03-01 RS RS20240693A patent/RS65707B1/sr unknown
- 2017-03-01 FI FIEP20208373.9T patent/FI3800257T3/fi active
- 2017-03-01 EP EP24159464.7A patent/EP4389221A3/en active Pending
- 2017-03-01 CN CN201780014078.0A patent/CN108778344A/zh active Pending
- 2017-03-01 CA CA3014776A patent/CA3014776A1/en active Pending
- 2017-03-01 US US16/081,818 patent/US10597658B2/en active Active
- 2017-03-01 SI SI201731528T patent/SI3800257T1/sl unknown
- 2017-03-01 SM SM20240253T patent/SMT202400253T1/it unknown
- 2017-03-01 HU HUE20208373A patent/HUE066977T2/hu unknown
- 2017-03-01 EP EP17760733.0A patent/EP3423107A4/en not_active Withdrawn
- 2017-03-01 ES ES20208373T patent/ES2981765T3/es active Active
- 2017-03-01 PT PT202083739T patent/PT3800257T/pt unknown
- 2017-03-01 LT LTEP20208373.9T patent/LT3800257T/lt unknown
- 2017-03-01 DK DK20208373.9T patent/DK3800257T3/da active
- 2017-03-01 JP JP2018543209A patent/JP7536272B2/ja active Active
- 2017-03-01 WO PCT/US2017/020241 patent/WO2017151795A1/en not_active Ceased
- 2017-03-01 PL PL20208373.9T patent/PL3800257T3/pl unknown
- 2017-03-01 HR HRP20240765TT patent/HRP20240765T1/hr unknown
-
2022
- 2022-10-07 JP JP2022162516A patent/JP2022176378A/ja not_active Withdrawn
-
2025
- 2025-04-02 JP JP2025061328A patent/JP2025096365A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sierra et al. | Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity | |
| Pariente et al. | Efficient virus extinction by combinations of a mutagen and antiviral inhibitors | |
| Bracho et al. | Contribution of Taq polymerase-induced errors to the estimation of RNA virus diversity | |
| Morshed et al. | Fowl adenoviruses D and E cause inclusion body hepatitis outbreaks in broiler and broiler breeder pullet flocks | |
| Borrego et al. | Lethal mutagenesis of Rift Valley fever virus induced by favipiravir | |
| Carrillo et al. | Genetic and phenotypic variation of foot-and-mouth disease virus during serial passages in a natural host | |
| CA2646026C (en) | Nucleic acid primers and probes for detecting human and avian influenza viruses | |
| Levina et al. | High antiviral effect of TiO2· PL–DNA nanocomposites targeted to conservative regions of (−) RNA and (+) RNA of influenza A virus in cell culture | |
| US8691781B2 (en) | Compositions for treating respiratory viral infections and their use | |
| PE20220574A1 (es) | Oligonucleotidos gapmer modificados y metodos de uso | |
| JP2006512906A5 (https=) | ||
| JP2016533172A5 (https=) | ||
| Conrardy et al. | Molecular detection of adenoviruses, rhabdoviruses, and paramyxoviruses in bats from Kenya | |
| JP2019511471A5 (https=) | ||
| Ishida et al. | Establishment of a reverse genetics system for influenza D virus | |
| Schweiger et al. | Reassortment between human A (H3N2) viruses is an important evolutionary mechanism | |
| Broto et al. | Type I interferon acts as a major barrier to the establishment of persistent infectious Bursal disease virus infections | |
| Bradfute | The discovery and development of novel treatment strategies for filoviruses | |
| US20160281089A1 (en) | Prevention of viral infectivity | |
| Wang et al. | Increased substitution rate in H5N1 avian influenza viruses during mass vaccination of poultry | |
| FI3800257T3 (fi) | Pan-genotyyppisiä aineita influenssavirusta vastaan ja menetelmiä niiden käyttämiseksi | |
| Fenwick et al. | Resistance studies with HIV-1 non-catalytic site integrase inhibitors | |
| TWI670064B (zh) | 抗病毒劑及治療病毒感染之方法 | |
| Wang et al. | Enhanced antiviral ability by a combination of zidovudine and short hairpin RNA targeting avian leukosis virus | |
| Hartawan et al. | Improving siRNA design targeting nucleoprotein gene as antiviral against the Indonesian H5N1 virus |